AgomAb Therapeutics N.V. American Depositary Shares (AGMB) Stock Price & Analysis

AgomAb Therapeutics N.V. American Depositary Shares (AGMB) Healthcare & Pipeline Overview

AgomAb Therapeutics N.V. specializes in developing innovative disease-modifying therapies for chronic fibrotic diseases, leveraging unique mechanisms of action to address significant unmet medical needs in immunology and inflammation.

What Is the Investment Thesis for AGMB?

The company's lead candidate, Ontunisertib (AGMB-129), is in Phase 2a trials, potentially positioning it for market entry within the next few years, contingent upon successful trial outcomes. Additionally, the company's unique approach to targeting fibrosis through agonistic antibodies could lead to breakthroughs in treatment, enhancing its competitive positioning. However, investors should remain cognizant of the inherent risks associated with clinical-stage drug development, including potential trial failures and regulatory hurdles that could impact timelines and market entry.

Based on FMP financials and quantitative analysis

AGMB Key Highlights

Clinical-stage pipeline with two candidates in trials: AGMB-129 in Phase 2a and AGMB-447 in Phase 1.

• Focus on chronic fibrotic diseases, addressing significant unmet medical needs.
• Incorporated in 2017, showcasing a relatively young but innovative company.
• Headquartered in Antwerp, Belgium, with a specialized team of 57 employees.

Who Are AGMB's Competitors?

AGMB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AGMB's Key Strengths?

Innovative pipeline targeting chronic fibrotic diseases with high unmet needs.

• Experienced leadership team with expertise in biopharmaceutical development.
• Strong preclinical data supporting the efficacy of drug candidates.
• Strategic focus on disease-modifying therapies, setting the company apart.

What Are AGMB's Weaknesses?

Limited financial resources as a clinical-stage company.

• Dependence on successful clinical trial outcomes for future growth.
• Potential challenges in regulatory approvals and market entry.
• Small team size may limit operational capacity and scalability.

What Are the Key Risks for AGMB?

Negative return on equity (-19.7%) — the business is not currently generating profit on shareholder capital.

• Clinical trial failures could adversely affect the company's product pipeline and market prospects.
• Regulatory challenges may delay the approval process for drug candidates.
• Competition from established biopharmaceutical companies could impact market entry and pricing strategies.
• Market volatility and economic conditions may affect funding and investment opportunities.

What Threats Does AGMB Face?

• Intense competition from established biopharmaceutical companies with similar focus.
• Risk of clinical trial failures impacting product pipeline and investor confidence.
• Regulatory hurdles that may delay product approvals and commercialization.
• Market volatility affecting funding and investment opportunities.

What Are AGMB's Competitive Advantages?

• Unique focus on chronic fibrotic diseases, an area with limited effective treatments.
• Innovative therapeutic approaches leveraging growth factor modulation.
• Strong intellectual property potential surrounding proprietary drug candidates.
• Experienced leadership team with a track record in biopharmaceutical development.
• Strategic location in Belgium, a hub for biotechnology innovation and research.

What Does AGMB Do?

AgomAb Therapeutics N.V., founded in 2017 and headquartered in Antwerp, Belgium, is a clinical-stage biopharmaceutical company dedicated to developing novel disease-modifying therapies for immunology and inflammatory diseases. The company primarily focuses on chronic fibrotic indications that present significant unmet medical needs. AgomAb's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, currently in Phase 2a clinical trials for Fibrostenosing Crohn's disease. Additionally, AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1, is in Phase 1 clinical trials for idiopathic pulmonary fibrosis. The company is also developing AGMB-101, a HGF-mimetic monoclonal antibody that stimulates the MET receptor, demonstrating antifibrotic and regenerative activity in preclinical models. AgomAb's innovative approach positions it uniquely within the biotechnology sector, particularly in the treatment of fibrotic diseases, an area characterized by high unmet needs and limited effective therapies. With a dedicated team of 57 employees, AgomAb is poised to make significant contributions to the field of immunology and inflammation through its targeted therapeutic strategies.

What Products and Services Does AGMB Offer?

• Develop novel therapies for immunology and inflammatory diseases.
• Focus on chronic fibrotic conditions with significant unmet medical needs.
• Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
• Utilize unique mechanisms of action to target fibrosis and promote regenerative health.
• Advance a diverse pipeline of product candidates at various stages of development.
• Engage in research collaborations to enhance therapeutic development.

How Does AGMB Make Money?

• Generate revenue through the development and commercialization of innovative biopharmaceutical products.
• Leverage partnerships with larger pharmaceutical companies for co-development and distribution.
• Focus on clinical trial milestones to attract investment and funding.
• Explore opportunities for licensing agreements once products are ready for market.
• Aim for strategic collaborations to enhance research capabilities and market access.

What Industry Does AGMB Operate In?

The biotechnology industry is characterized by rapid innovation and significant investment in research and development, particularly in therapeutic areas with high unmet medical needs. Chronic fibrotic diseases, such as idiopathic pulmonary fibrosis and Fibrostenosing Crohn's disease, are gaining increasing attention due to their complex pathophysiology and the lack of effective treatments. The global market for fibrosis-related therapies is expected to grow substantially, driven by advancements in drug development and a better understanding of disease mechanisms. AgomAb Therapeutics N.V. is well-positioned within this competitive landscape, leveraging its unique therapeutic approaches to address these pressing healthcare challenges.

Who Are AGMB's Key Customers?

• Healthcare providers and hospitals seeking advanced treatment options for patients.
• Patients suffering from chronic fibrotic diseases in need of effective therapies.
• Pharmaceutical companies interested in partnerships for drug development.
• Investors looking for opportunities in innovative biopharmaceutical companies.
• Regulatory bodies requiring compliance with clinical and safety standards.

Return on equity for AgomAb Therapeutics N.V. American Depositary Shares stands at -19.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -12.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -7.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 12.88 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -9.5%, the inverse of the P/E and a quick read on earnings relative to price.

Company Profile

AgomAb Therapeutics N.V. American Depositary Shares operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Antwerp, BE. The company is led by CEO Tim Knotnerus. AGMB has traded publicly since 2026.

AgomAb Therapeutics N.V. American Depositary Shares has missed Wall Street's EPS estimate in 2 of its last 3 reported quarters — a mixed record worth weighing. Reported results have landed about 2962.7% below estimates on average.

Wall Street analysts project AgomAb Therapeutics N.V. American Depositary Shares revenue of about $443K for fiscal 2026, with EPS near $-1.75. The estimate reflects 6 contributing analysts.

AGMB Financials

AGMB Latest News

AGMB Analyst Consensus

AGMB MoonshotScore

What Investors Ask About AgomAb Therapeutics N.V. American Depositary Shares (AGMB) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources